ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
61,279.38
0.79%
S&P 500
5,222.68
0.16%
Dow Jones
39,512.84
0.32%
US Dollar vs Yen
155.775
0.00%
Brent Oil
82.585
0.00%
Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Madrigal Pharmaceuticals Inc (MDGL)

  7. Madrigal Pharmaceuticals Inc (MDGL) ニュース

MDGL

Madrigal Pharmaceuticals (MDGL)

Madrigal Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:MDGL
日付受信時刻ニュースソース見出しコード企業名
2024/05/0805 : 36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/05/0805 : 34Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/05/0805 : 29Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/05/0722 : 00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/05/0720 : 06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/05/0720 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/04/2505 : 00GlobeNewswire Inc.Madrigal Statement on the Passing of Dr. Stephen HarrisonNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/04/2321 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/04/1705 : 05GlobeNewswire Inc.Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/04/0921 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver FibrosisNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/04/0405 : 05GlobeNewswire Inc.Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/03/1912 : 58GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public OfferingNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/03/1905 : 04GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Proposed Public OfferingNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/03/1520 : 30IH Market NewsAdobe Stock Drops Following Below-Estimate Projections, Cardlytics Surges with Unexpected Profit, and More NewsNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/03/1505 : 15GlobeNewswire Inc.Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver FibrosisNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/03/0706 : 05GlobeNewswire Inc.Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/03/0522 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver FibrosisNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/02/2821 : 10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/02/2821 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/02/2821 : 01GlobeNewswire Inc.Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial OfficerNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/02/2821 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/02/2820 : 32Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/02/2122 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/02/1504 : 50Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/02/1423 : 21Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/02/1407 : 55Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/02/0822 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of MedicineNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/02/0706 : 05GlobeNewswire Inc.Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/01/3007 : 25Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/01/2922 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Additions to Its Leadership TeamNASDAQ:MDGLMadrigal Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MDGL

最近閲覧した銘柄

NYSE
XOM
Exxon Mobil
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
AXP
American Express
CCOM
SILVER
SILVER
USOTC
BASFY
BASF (QX)
NASDAQ
MSFT
Microsoft
NASDAQ
TSLA
Tesla
USOTC
ADDYY
Adidas (QX)
USOTC
BNPQY
BNP Paribas (QX)
NYSE
BAC
Bank of America
AMEX
XLE
Energy Select Sector SPDR
CCOM
US500
US 500
COIN
SOLUSD
Solana
CCOM
US100
US Tech 100
FX
USDJPY
US Dollar vs Yen
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有